AU676166B2 - Immediate early HSV-2 viral protein ICP27 as vaccine - Google Patents

Immediate early HSV-2 viral protein ICP27 as vaccine Download PDF

Info

Publication number
AU676166B2
AU676166B2 AU43264/93A AU4326493A AU676166B2 AU 676166 B2 AU676166 B2 AU 676166B2 AU 43264/93 A AU43264/93 A AU 43264/93A AU 4326493 A AU4326493 A AU 4326493A AU 676166 B2 AU676166 B2 AU 676166B2
Authority
AU
Australia
Prior art keywords
hsv
protein
icp27
ctl
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU43264/93A
Other languages
English (en)
Other versions
AU4326493A (en
Inventor
Marguerite Koutsoukos
Pietro Pala
Moncef Slaoui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Publication of AU4326493A publication Critical patent/AU4326493A/en
Application granted granted Critical
Publication of AU676166B2 publication Critical patent/AU676166B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AU43264/93A 1992-06-25 1993-06-15 Immediate early HSV-2 viral protein ICP27 as vaccine Ceased AU676166B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9213559 1992-06-25
GB9213559A GB9213559D0 (en) 1992-06-25 1992-06-25 Vaccines
PCT/EP1993/001525 WO1994000575A1 (en) 1992-06-25 1993-06-15 Immediate early hsv-2 viral protein icp27 as vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU17855/97A Division AU1785597A (en) 1992-06-25 1997-04-14 Immediate early HSV-2 viral protein ICP27 as vaccine

Publications (2)

Publication Number Publication Date
AU4326493A AU4326493A (en) 1994-01-24
AU676166B2 true AU676166B2 (en) 1997-03-06

Family

ID=10717757

Family Applications (2)

Application Number Title Priority Date Filing Date
AU43264/93A Ceased AU676166B2 (en) 1992-06-25 1993-06-15 Immediate early HSV-2 viral protein ICP27 as vaccine
AU17855/97A Abandoned AU1785597A (en) 1992-06-25 1997-04-14 Immediate early HSV-2 viral protein ICP27 as vaccine

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU17855/97A Abandoned AU1785597A (en) 1992-06-25 1997-04-14 Immediate early HSV-2 viral protein ICP27 as vaccine

Country Status (11)

Country Link
EP (1) EP0649470A1 (es)
JP (1) JPH07508648A (es)
KR (1) KR950702244A (es)
CN (1) CN1092812A (es)
AU (2) AU676166B2 (es)
CA (1) CA2138996A1 (es)
GB (1) GB9213559D0 (es)
MX (1) MX9303771A (es)
NZ (1) NZ253138A (es)
TW (1) TW269635B (es)
WO (1) WO1994000575A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1659178T1 (sl) * 1998-02-05 2010-07-30 Glaxosmithkline Biolog Sa Postopek za čiščenje ali proizvodnjo MAGE proteina
DK1092779T3 (da) * 1999-10-11 2010-02-15 Pasteur Institut Lentiviirusvektorer til fremstilling af immunterapeutiske præparater
US7196066B1 (en) 1999-11-03 2007-03-27 Powderject Vaccines, Inc. DNA-vaccines based on constructs derived from the genomes of human and animal pathogens
JP2007505147A (ja) * 2003-09-12 2007-03-08 アンティジェニクス インコーポレーテッド 単純ヘルペスウイルス感染の治療および予防用ワクチン

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MCGEOCH D J ET AL (1991) JOURNAL OF GENERAL VIROLOGY *
VOL 72, PAGES 3057-3075 *

Also Published As

Publication number Publication date
AU1785597A (en) 1997-06-19
AU4326493A (en) 1994-01-24
TW269635B (es) 1996-02-01
MX9303771A (es) 1994-05-31
CA2138996A1 (en) 1994-01-06
GB9213559D0 (en) 1992-08-12
NZ253138A (en) 1995-10-26
CN1092812A (zh) 1994-09-28
JPH07508648A (ja) 1995-09-28
EP0649470A1 (en) 1995-04-26
WO1994000575A1 (en) 1994-01-06
KR950702244A (ko) 1995-06-19

Similar Documents

Publication Publication Date Title
US20040228842A1 (en) Compositions and methods for cytomegalovirus treatment
JPH06506705A (ja) 再発性ｈｓｖ感染用の免疫療法
EP2263686B1 (en) Pharmaceutical compositions comprising immunologically active herpes simplex virus (HSV) protein fragments
KR20150014500A (ko) Hsv-2 백신
US20180207261A1 (en) Human herpesvirus immunotherapy
NO20021479L (no) Immunologiske signifikante herpes simplex virus antigener og metoder for å identifisere og å bruke dem
EP1047446B1 (en) Vaccine composition for herpes simplex virus and methods of using
JP5845191B2 (ja) 単純ヘルペスウイルスワクチン
JPH084508B2 (ja) 組み換えワクチニアウイルス
WO1995016779A9 (en) Herpes-symplex-virus type 2 icp4 protein and its use in a vaccine composition
JPH08508728A (ja) パピローマウィルスに基づく医薬品
CN111925994B (zh) 一种dp71l基因缺失的重组非洲猪瘟病毒及其制备方法和应用
US7638132B2 (en) Highly safe smallpox vaccine virus and vaccinia virus vector
CA2086740A1 (en) Equine herpesvirus-4 tk-vaccine
AU676166B2 (en) Immediate early HSV-2 viral protein ICP27 as vaccine
Aravind et al. Protective effects of recombinant glycoprotein D based prime boost approach against duck enteritis virus in mice model
CN114657154B (zh) 一种羊传染性脓疱病毒减毒株的制备方法及其应用
JP2023545524A (ja) 組換えｈｖｔ及びその使用
WO2006113927A2 (en) Immunogenic vaccinia peptides and methods of using same
US10172933B2 (en) Mosaic vaccines for serotype a foot-and-mouth disease virus
AU672870B2 (en) Vaccines against varicella-zoster virus (VZV)
GB2062463A (en) Babesiosis vaccine
CN1222393A (zh) 疫苗组合物及其制备方法
Zajac Identification of African Swine Fever Virus antigens for development of an efficacious subunit vaccine
KR20230153047A (ko) 톡소포자충의 항원 rop4를 포함하는 재조합 백시니아 바이러스 백신

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired